Scleroderma or systemic sclerosis (SSc) is a connective tissue disease (CTD) associated with fibrosing and vascular complications involving multiple organs. The care of these patients in the critical care setting is frequently challenging due to multiple complications and refractory organ involvement. However, awareness of specific organ involvement associated with scleroderma can allow many complications to be anticipated and effectively treated. Cardiac involvement can lead to arrthymias and heart failure, whereas pulmonary involvement can be associated with pulmonary arterial hypertension, fibrosis, or both. Renal vascular disease and scleroderma renal crisis (SRC), once a uniformly fatal complication, is particularly important to recognize early, as it can be treated successfully. Gastrointestinal involvement can lead to bleeding, aspiration, obstruction, and malabsorption. Severe Raynaud may lead to digital ischemia and gangrene. Therapies must target involved organ system or organ systems. Corticosteroids, a mainstay for related CTDs, do not typically provide any benefit and may cause harm. Vasodilators can effectively treat vascular complications but must target the appropriate vascular bed. Proactive utilization of proton pump inhibitors, recognition of bleeding from gastrointestinal vascular ectasia, and nutritional support can considerably ameliorate gastrointestinal morbidities. Effective treatment of fibrotic complications remains elusive and is the current frontier for scleroderma therapeutics.
Steen VD, Medsger TA Jr.Severe organ involvement in systemic sclerosis with diffuse scleroderma . Arthritis Rheum. 2000;43(11): 2437-2444.
2.
Steen VD, Follansbee WP, Conte CG, Medsger TA Jr.Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum. 1996;39(4): 677-681.
3.
Follansbee WP , Curtiss EI, Rahko PS, et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med. 1985 ;79(2):183-192.
4.
Fernandes F. , Ramires FJ, Arteaga E., Ianni BM, Bonfa ES, Mady C.Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail. 2003;9(4):311-317.
5.
Lekakis J., Mavrikakis M., Emmanuel M., et al. Cold-induced coronary Raynaud’s phenomenon in patients with systemic sclerosis. Clin Exp Rheumatol. 1998;16(2):135-140.
6.
Coghlan JG, Mukerjee D.The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol. 2001 ;13(6):495-499.
7.
Vignaux O., Allanore Y., Meune C., et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis. 2005;64(9): 1268-1273.
8.
Kostis JB, Seibold JR, Turkevich D., et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis . Am J Med. 1988; 84(6):1007-1015.
9.
Williams MH, Handler CE, Akram R., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006; 27(12):1485-1494.
10.
Steiner JA, Cooper R., Gear JS, Ledingham JGVascular symptoms in patients with primary Raynaud’s phenomenon are not exacerbated by propranolol or labetalol. Br J Clin Pharmacol . 1979;7(4):401-403.
11.
Byers RJ, Marshall DA, Freemont AJPericardial involvement in systemic sclerosis. Ann Rheum Dis . 1997;56(6):393-394.
12.
D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
Rich S., Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study . Ann Intern Med. 1987; 107(2):216-223.
15.
Simonneau G. , Galie N., Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 suppl S): 5S-12S.
16.
Chin KM, Kim NH, Rubin LJThe right ventricle in pulmonary hypertension. Coron Artery Dis. 2005;16(1):13-18.
17.
Budhiraja R. , Tuder RM, Hassoun PMEndothelial dysfunction in pulmonary hypertension . Circulation. 2004;109(2):159-165.
18.
Humbert M., Sitbon O., Simonneau G.Treatment of pulmonary arterial hypertension. N Engl J Med . 2004;351(14):1425-1436.
19.
Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SEHemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003 ;123(2):344-350.
20.
Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006 ;54(9):3043-3050.
21.
MacGregor AJ , Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival . Rheumatology (Oxford). 2001;40(4): 453-459.
22.
Deng Z., Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67(3):737-744.
23.
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germ-line mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000;26(1):81-84.
24.
Murata I., Kihara H., Shinohara S., Ito K.Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J. 1992;56(10):983-991.
25.
Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996; 110(6):1515-1519.
26.
Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr.Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis . Arthritis Rheum. 1986;29(4):515-524.
27.
Hachulla E. , Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792-3800.
28.
Mukerjee D. , St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088-1093.
29.
Mayes MDScleroderma epidemiology. Rheum Dis Clin North Am . 2003;29(2):239-254.
30.
Steen VD, Medsger TAChanges in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-944.
31.
Giaid A., Saleh D.Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214-221.
32.
Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159(6):1925-1932.
33.
Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732-1739.
Vane JR, Anggard EE, Botting RMRegulatory functions of the vascular endothelium. N Engl J Med. 1990;323(1):27-36.
36.
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334(5):296-301.
37.
McLaughlin VV, Genthner DE, Panella MM, Rich S.Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension . N Engl J Med. 1998;338(5):273-277.
38.
Rubin LJ, Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990;112(7):485-491.
39.
McLaughlin VV, Shillington A., Rich S.Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
40.
Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol . 2002;40(4): 780-788.
41.
Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-434.
42.
Farber HW, Graven KK, Kokolski G., Korn JHPulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol . 1999;26(5): 1195-1196.
43.
Palmer SM, Robinson LJ, Wang A., Gossage JR, Bashore T., Tapson VFMassive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 1998;113(1):237-240.
44.
Dorfmuller P., Humbert M., Perros F., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007; 38(6):893-902.
45.
Simonneau G. , Barst RJ, Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-804.
46.
Tapson VF, Gomberg-Maitland M., McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129(3):683-688.
47.
Oudiz RJ, Farber HWDosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J.2009;157(4):625-635.
48.
Kallen AJ, Lederman E., Balaji A., et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008;29(4):342-349.
49.
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension[see comment] [erratum appears in N Engl J Med 2002 Apr 18;346(16):1258]. N Engl J Med. 2002;346(12):896-903.
50.
Channick RN , Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet . 2001;358(9288):1119-1123.
51.
Galie N., Olschewski H., Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-3019.
52.
Denton CP, Humbert M., Rubin L., Black CMBosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006 ;65(10): 1336-1340.
53.
Galie N., Ghofrani HA, Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension . N Engl J Med. 2005;353(20): 2148-2157.
54.
Badesch DB, Hill NS, Burgess G., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 ;34(12):2417-2422.
55.
McLaughlin VV , Oudiz RJ, Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11): 1257-1263.
56.
Hoeper MM, Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691-694.
57.
Simonneau G. , Rubin LJ, Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial . Ann Intern Med. 2008 ;149(8):521-530.
58.
Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29(3):469-475.
59.
Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80(5):1198-1206.
60.
Fuster V., Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RLPrimary pulmonary hypertension: natural history and the importance of thrombosis . Circulation. 1984;70(4):580-587.
61.
Rich S., Kaufmann E., Levy PSThe effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 ;327(2):76-81.
62.
Berezne A., Valeyre D., Ranque B., Guillevin L., Mouthon L.Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide? Ann N Y Acad Sci . 2007;1110:271-284.
63.
van Laar JM , Stolk J., Tyndall A.Scleroderma lung: pathogenesis, evaluation and current therapy. Drugs. 2007 ;67(7):985-996.
64.
Strange C., Highland KBInterstitial lung disease in the patient who has connective tissue disease . Clin Chest Med. 2004;25(3): 549-559, vii.
65.
White B.Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2003;29(2):371-390.
66.
Latsi PI, Wells AUEvaluation and management of alveolitis and interstitial lung disease in scleroderma . Curr Opin Rheumatol. 2003 ;15(6):748-755.
67.
Nannini C., West CP, Erwin PJ, Matteson ELEffects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies . Arthritis Res Ther. 2008;10(5):R124.
68.
Tashkin DP, Elashoff R., Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease . N Engl J Med. 2006;354(25):2655-2666.
69.
Schachna L. , Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006;54(12):3954-3961.
70.
Simms RW, Korn JHSystemic sclerosis: the spectrum, immunopathogenesis, clinical features, and treatment. In: Adu D, Emery P, Madaio M, eds. Rheumatology and the kidney. Oxford: Oxford University Press;2001:275-293.
71.
Steen V., Steen V.Scleroderma renal crisis.[comment]. Indian J Med Sci . 2007;61(2):71-72.
Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases . Medicine. 1983;62(6):335-352.
76.
Thurm CA, Wigley FM, Dole WP, Wise RAFailure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. Am J Med. 1991;90:547-552.
77.
Wigley FM, Flavahan N.Raynaud’s phenomenon. Rheum Dis Clin North Am . 1996;22:4;765-781.
78.
Hummers LK, Wigley FM, Hummers LK, Wigley FMManagement of Raynaud’s phenomenon and digital ischemic lesions in scleroderma . Rheum Dis Clin North Am. 2003; 29(2):293-313.
79.
Barr WG, Fahey PJReduction of pulmonary capillary blood volume following cold exposure in patients with Raynaud’s phenomenon. Chest. 1988 ;94(6):1195-1199.
80.
Biondi ML, Marasini B., Bassani C., Agostoni A.Increased plasma endothelin levels in patients with Raynaud’s phenomenon . N Engl J Med. 1991;324(16):1139-1140.
81.
Brain SD, Crossman DC, Buckley TL, Williams TJEndothelin-1: demonstration of potent effects on the microcirculation of humans and other species. J Cardiovasc Pharmacol. 1989; 13(suppl 5):S147-S150.
82.
Cimminiello C., Milani M., Uberti T., Arpaia G., Perolini S., Bonfardeci G.Endothelin, vasoconstriction, and endothelial damage in Raynaud’s phenomenon. Lancet. 1991;337(8733): 114-115.
83.
Freedman RR , Sabharwal SC, Desai N., Wenig P., Mayes M.Increased a-adrenergic responsiveness in idiopathic Raynaud’s disease. Arthritis Rheum. 1989;32(1):61-65.
84.
Graafsma SJ , Wollersheim H., Droste HT, et al. Adrenoceptors on blood cells from patients with primary Raynaud’s phenomenon. Clin Sci . 1991;80(4):325-331.
85.
Guimaraes S. , Moura D.Vascular adrenoceptors: an update .[erratum appears in Pharmacol Rev2001 Sep;53(3):451]. Pharmacol Rev. 2001;53(2):319-356.
86.
Kanno K., Hirata Y., Emori T., et al. Endothelin and Raynaud’s phenomenon. Am J Med. 1991;90(1):130-132.
87.
Kiowski W., Lüscher TF, Linder L., Bühler FREndothelin-1-induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor . Circulation. 1991;83(2):469-475.
88.
Smyth AE, Bell AL, Bruce IN, McGrann S., Allen JADigital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud’s phenomenon. Ann Rheum Dis. 2000; 59(11):870-874.
89.
Minchenko A. , Bauer T., Salceda S., Caro J.Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest . 1994;71(3):374-379.
90.
Mittag M., Beckheinrich P., Haustein UFSystemic sclerosis-related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol. 2001;81(4):294-297.
91.
Distler JH, Kalden JR, Gray S., Distler O.[Vascular changes in the pathogenesis of systemic sclerosis]. Z Rheumatol. 2004;63(6): 446-450.
92.
Hachulla E. , Clerson P., Launay D., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study . J Rheumatol . 2007;34(12): 2423-2430.
93.
Ostojic P., Damjanov N., Pavlov-Dolijanovic S., et al. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease. Clin Hemorheol Microcirc. 2004;31(4):281-285.
94.
Moore SC, Desantis ER, Moore SC, Desantis ERH.Treatment of complications associated with systemic sclerosis. Am J Health Syst Pharm. 2008;65(4):315-321.
95.
Varga J.New hope for systemic sclerosis patients with digital ulcers. Curr Rheumatol Rep. 2005;7(2):127-128.
96.
Zachariae H. , Halkier-Sorensen L., Bjerring P., Heickendorff L.Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol. 1996;76(3):236-238.
97.
Bluestone R. , Macmahon M., Dawson JMSystemic sclerosis and small bowel involvement . Gut. 1969;10(3):185-193.
98.
Kaye SA, Seifalian AM, Lim SG, Hamilton G., Black CMIschaemia of the small intestine in patients with systemic sclerosis: Raynaud’s phenomenon or chronic vasculopathy? QJM. 1994 ;87(8):495-500.
99.
Kaye SA, Lim SG, Taylor M., Patel S., Gillespie S., Black CMSmall bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol . 1995;34(3):265-269.
100.
Sjogren RWGastrointestinal motility disorders in scleroderma . Arthritis Rheum. 1994;37(9):1265-1282.
101.
Bloch F., Leport J., Mallet L., Fiessinger JN, Housset E., Petite JP[Spontaneous pneumoperitoneum in scleroderma]. Gastroenterol Clin Biol. 1984;8(6-7):557-559.
102.
Ebert EC, Ruggiero FM, Seibold JRIntestinal perforation. A common complication of scleroderma. Dig Dis Sci. 1997;42(3):549-553.
103.
Watson M., Hally RJ, McCue PA, Varga J., Jimenez SAGastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheumat. 1996 ;39(2):341-346.
104.
Calamia KT , Scolapio JS, Viggiano TR. Endoscopic YAG laser treatment of watermelon stomach (gastric antral vascular ectasia) in patients with systemic sclerosis. Clinical Exp Rheumatol. 2000;18(5):605-608.
105.
Shalev T., Haviv Y., Segal E., et al. Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases. Clin Exp Rheumatol. 2006;24(4):380-386.
